Europe
Tagrisso demonstrated an 82% reduction in the risk of central nervous system recurrence or death. The safety and tolerability of the product in the Phase III trial was consistent with previous trials in the metastatic EGFRm NSCLC setting.
Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
LAVA Therapeutics is now financially poised to advance their bispecific antibodies to engage Vγ9Vδ2 T cells in the fight against cancer thanks to an infusion of capital from an oversubscribed $83 million Series C financing.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.
PRESS RELEASES